% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Platten:143705,
author = {M. Platten$^*$ and E. A. A. Nollen and U. F. Röhrig and F.
Fallarino and C. Opitz$^*$},
title = {{T}ryptophan metabolism as a common therapeutic target in
cancer, neurodegeneration and beyond.},
journal = {Nature reviews / Drug discovery Drug discovery [...]},
volume = {18},
number = {5},
issn = {1474-1784},
address = {London},
publisher = {Nature Publ. Group},
reportid = {DKFZ-2019-01278},
pages = {379 - 401},
year = {2019},
abstract = {L-Tryptophan (Trp) metabolism through the kynurenine
pathway (KP) is involved in the regulation of immunity,
neuronal function and intestinal homeostasis. Imbalances in
Trp metabolism in disorders ranging from cancer to
neurodegenerative disease have stimulated interest in
therapeutically targeting the KP, particularly the main
rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1),
IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as
kynurenine monooxygenase (KMO). However, although
small-molecule IDO1 inhibitors showed promise in early-stage
cancer immunotherapy clinical trials, a phase III trial was
negative. This Review summarizes the physiological and
pathophysiological roles of Trp metabolism, highlighting the
vast opportunities and challenges for drug development in
multiple diseases.},
subtyp = {Review Article},
cin = {D170 / B350 / L101},
ddc = {610},
cid = {I:(DE-He78)D170-20160331 / I:(DE-He78)B350-20160331 /
I:(DE-He78)L101-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30760888},
doi = {10.1038/s41573-019-0016-5},
url = {https://inrepo02.dkfz.de/record/143705},
}